LIG Nex1 Co., Ltd. (KRX:079550)

Market Cap	12.90T
Revenue (ttm)	3.42T
Net Income (ttm)	245.36B
Shares Out	21.79M
EPS (ttm)	11,257.99
PE Ratio	52.58
Forward PE	43.46
Dividend	2,400.00 (0.38%)
Ex-Dividend Date	Dec 27, 2024

Volume	160,271
Average Volume	130,355
Open	621,000
Previous Close	628,000
Day's Range	581,000 - 624,000
52-Week Range	168,700 - 650,000
Beta	0.68
RSI	53.28
Earnings Date	Jul 25, 2025

About Revance Therapeutics

LIG Nex1 Co., Ltd. develops and produces various weapon systems worldwide. The company offers precision guided munitions, which include ground-based guided missiles; ship-launched/air-launched guided missiles; and underwater guided missiles. It also provides intelligence, surveillance, and reconnaissance products that include radar systems, electronic optics/imaging radars, and SONAR surveillance systems. In addition, the company offers command and control systems, such as ground-based command and control systems for unmanned aerial systems, ta...

• Industry: Aerospace & Defense
• Sector: Industrials
• Founded: 1976
• Employees: 4,926
• Stock Exchange: Korea Stock Exchange
• Ticker Symbol: 079550

Financial Performance

In 2024, LIG Nex1's revenue was 3.28 trillion, an increase of 41.92% compared to the previous year's 2.31 trillion. Earnings were 221.71 billion, an increase of 26.72%.